Findings suggest that KLK6 overexpression in LUAD is driven in part by promoter hypomethylation and is closely linked to a neutrophil-dominant immunosuppressive microenvironment and may serve as a promising prognostic biomarker and a potential therapeutic target for LUAD.
Abstract
INTRODUCTION
Lung adenocarcinoma (LUAD) is the most prevalent histological subtype of lung cancer and is associated with poor survival despite advances in targeted therapies. Kallikrein-related peptidase 6 (KLK6) has been implicated in several malignancies, but its expression pattern, clinical relevance, and biological function in LUAD remain incompletely characterized. This study aimed to evaluate KLK6 expression and its associations with prognosis, epigenetic regulation, immune infiltration, and migratory phenotypes in LUAD.
Methods
RNA-seq expression and clinical data were obtained from The Cancer Genome Atlas (TCGA), Genotype-Tissue Expression (GTEx), and Gene Expression Omnibus (GEO) databases. KLK6 expression was analyzed in relation to clinicopathological parameters, survival outcomes, promoter methylation status (via UALCAN), and tumor-infiltrating immune cell abundance (via TIMER2.0). In vitro, KLK6 was knocked down using shRNA in A549 and H1299 LUAD cell lines. Cell migration was assessed by transwell assays, and the expression of Epithelial-Mesenchymal Transition (EMT)- and Wnt signaling-related markers was examined by qRT-PCR and Western blotting.
Results
KLK6 expression was significantly upregulated in LUAD tissues compared with normal lung tissues. High KLK6 expression was associated with poorer overall survival (HR = 1.52, P = 0.009) and disease-specific survival (HR = 1.55, P = 0.03). ROC analysis showed that KLK6 discriminated stage I LUAD from normal tissues with an AUC of 0.73. Promoter hypomethylation was observed in LUAD tumors and correlated with increased KLK6 expression. Immune infiltration analysis revealed that KLK6-high tumors exhibited reduced B-cell infiltration and increased neutrophil infiltration. Functional experiments demonstrated that KLK6 knockdown significantly suppressed cell migration, accompanied by increased E-cadherin and decreased N-cadherin, Vimentin, Wnt5a, and β-catenin expression.
Discussion
These findings suggest that KLK6 overexpression in LUAD is driven in part by promoter hypomethylation and is closely linked to a neutrophil-dominant immunosuppressive microenvironment. Furthermore, KLK6 appears to promote LUAD cell migration through EMT- and Wnt-related signaling pathways. Collectively, these multi-layered data position KLK6 as a potential driver of aggressive tumor behavior and a candidate biomarker for risk stratification.
Conclusion
KLK6 is aberrantly overexpressed in LUAD and is associated with poor prognosis and enhanced migratory capacity. It may serve as a promising prognostic biomarker and a potential therapeutic target for LUAD.
PRKX drives immune exhaustion in the GC1 subtype by stabilizing PD-L1 through phosphorylation-dependent inhibition of ubiquitination, thereby promoting immune evasion and targeting PRKX represents a potential strategy to overcome resistance to anti-PD-1 therapy.
Qi-Yue Wang, Yin-Qi Chen, Dong-Dong Huang et al.· Journal for ImmunoTherapy of...· 0 citations
Objective Lung adenocarcinoma (LUAD) is a highly aggressive malignancy originating from the bronchial epithelium or glandular tissues and represents the most rapidly increasing subtype of lung cancer worldwide. Its high incidence and mortality rates contribute to an overall unfavorable prognosis. Therapeutic options fo...
Wei Zhang, Li-Sha Ren, Huan-He Bai et al.· Frontiers in Oncology· 0 citations
Pancreatic adenocarcinoma (PDAC) is an abysmal disease, with a poor clinical outcome, largely due to limited life-extending treatments for patients. Notoriously, PDAC displays a T cell-suppressive tumor microenvironment where underlying molecular mechanisms that lead to this phenotype remain poorly understood. To unr...
Kimberly A. Kelly, Cody L. Wolf, Roxanne K. Ruiz et al.· Cancer Research· 0 citations
Serine/glycine-one-carbon (SGOC) metabolism is frequently altered in lung adenocarcinoma (LUAD), but its relationship to tumor behavior and predicted immunotherapy responsiveness remains incompletely defined. Metabolomic profiling of 23 paired LUAD and adjacent normal lung tissues was performed using internal extractiv...
Yang Zhang, Nuo Yan, De-Zhong Zhang et al.· Journal of Visualized Experi...· 0 citations
CDC20B may contribute to tumor progression in a context-dependent manner, with its prognostic impact varying across cancer types, and promoter hypomethylation emerges as a potential epigenetic driver of overexpression.
Hong-Rong Wu, Liang-Li Hong· Current Medicinal Chemistry· 0 citations
Findings indicate that ARG‐related molecular features are associated with GC prognosis and immune‐stromal characteristics, while EEF1A2 and TAGLN may represent candidate genes related to GC cell migration and invasion.
Z. Fu, Lin Sun, Xing Wang et al.· Chemical Biology and Drug De...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.